Cumulus Neuroscience

Executive Summary

Cumulus Neuroscience is a UK-based digital health company pioneering remote brain health monitoring through its NeuLogiq platform. NeuLogiq is a medical-grade, at-home data collection and analytics system designed to track functional brain health and disorders, addressing critical challenges in neuroscience by enabling continuous, real-world data capture outside clinical settings. Founded in 2017 and headquartered in Belfast, the company operates with 11-50 employees and targets a broad spectrum of neurological conditions, potentially reducing the need for frequent hospital visits and enabling earlier interventions. Despite limited public financial or clinical data, the platform's focus on flexibility and medical-grade accuracy positions it in a growing market for decentralized clinical trials and remote patient monitoring. The company's progress, partnerships, or regulatory milestones are not widely reported, making near-term visibility limited.

Upcoming Catalysts (preview)

• TBDFDA or CE Mark Clearance for NeuLogiq Platform35% success
• TBDStrategic Partnership with Pharma for Clinical Trial Use45% success
• TBDSeries A or B Funding Round Announcement50% success